Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
Ovation Science (OTC:OVATF) has strengthened its strategic partnership with Skinvisible Pharmaceuticals to develop innovative cannabinoid-based solutions for the obesity market, leveraging the patent-pending Invisicare® delivery technology. The enhanced collaboration maintains Ovation's exclusive worldwide rights to manufacture and distribute products using Skinvisible's technology.
The partnership focuses on THC-V (tetrahydrocannabivarin), showing promise as an appetite suppressant and metabolic function enhancer without psychoactive effects. The transdermal delivery system aims to reduce gastrointestinal side effects common in obesity treatments. This positions both companies to target the global obesity therapy market, projected to reach $150 billion by 2035.
Ovation Science (OTC:OVATF) ha rafforzato la sua partnership strategica con Skinvisible Pharmaceuticals per sviluppare soluzioni innovative a base di cannabinoidi per il mercato dell'obesità, sfruttando la tecnologia di rilascio Invisicare® in fase di brevetto. La collaborazione potenziata mantiene i diritti esclusivi mondiali di Ovation per la produzione e la distribuzione dei prodotti che utilizzano la tecnologia di Skinvisible.
La partnership si concentra su THC-V (tetraidrocannabivarin), che mostra potenziale come soppressore dell'appetito e miglioratore delle funzioni metaboliche senza effetti psicoattivi. Il sistema di somministrazione transdermica mira a ridurre gli effetti collaterali gastrointestinali comuni ai trattamenti dell'obesità. Ciò posiziona entrambe le aziende per rivolgersi al mercato globale della terapia dell'obesità, previsto raggiungere 150 miliardi di dollari entro il 2035.
Ovation Science (OTC:OVATF) ha reforzado su asociación estratégica con Skinvisible Pharmaceuticals para desarrollar soluciones innovadoras a base de cannabinoides para el mercado de la obesidad, aprovechando la tecnología de entrega Invisicare® con patente en trámite. La colaboración ampliada mantiene los derechos exclusivos mundiales de Ovation para la fabricación y distribución de productos que utilizan la tecnología de Skinvisible.
La alianza se centra en THC-V (tetrahidrocannabivarin), que muestra potencial como supresor del apetito y mejora de la función metabólica sin efectos psicoactivos. El sistema de administración transdérmica busca reducir los efectos secundarios gastrointestinales comunes en los tratamientos de obesidad. Esto posiciona a ambas empresas para dirigirse al mercado global de la terapia de la obesidad, que se estima alcanzará $150 mil millones para 2035.
Ovation Science (OTC:OVATF)가 Skinvisible Pharmaceuticals와의 전략적 파트너십을 강화해 인지버스 Invisicare® 전달 기술을 활용하여 비만 시장을 위한 혁신적인 칸나비노이드 기반 솔루션을 개발합니다. 확장된 협력은 Ovation이 Skinvisible 기술을 사용한 제품의 전 세계 독점 제조 및 유통 권리를 유지합니다.
이 파트너십은 THC-V(테트라하이드로칸나비바리닌)에 초점을 맞추며 식욕 억제 및 대사 기능 향상에 비심리적 효과를 보일 가능성을 보여줍니다. 경피 전달 시스템은 비만 치료에서 흔히 나타나는 위장 관련 부작용을 줄이는 것을 목표로 합니다. 이는 두 회사가 전 세계 비만 치료 시장에 진입할 수 있게 하며, 2035년까지 1,500억 달러에 이를 것으로 전망됩니다.
Ovation Science (OTC:OVATF) a renforcé son partenariat stratégique avec Skinvisible Pharmaceuticals afin de développer des solutions innovantes à base de cannabinoïdes pour le marché de l’obésité, en s’appuyant sur la technologie de délivrance Invisicare® en cours de brevet. Cette collaboration renforcée conserve les droits exclusifs mondiaux d’Ovation pour la fabrication et la distribution des produits utilisant la technologie de Skinvisible.
Le partenariat se concentre sur THC-V (tétrahydrocannabivarine), qui semble prometteur comme suppressant d’appétit et amélioreur de la fonction métabolique sans effets psychoactifs. Le système de délivrance transdermique vise à réduire les effets secondaires gastro-intestinaux courants dans les traitements de l’obésité. Cela positionne les deux entreprises pour cibler le marché mondial de la thérapie de l’obésité, estimé atteindre 150 milliards de dollars d’ici 2035.
Ovation Science (OTC:OVATF) hat seine strategische Partnerschaft mit Skinvisible Pharmaceuticals gestärkt, um innovative Kanabinoid-basierte Lösungen für den Obesitätsmarkt zu entwickeln und dabei die patentierbare Invisicare®-Liefertechnologie zu nutzen. Die erweiterte Zusammenarbeit sichert Ovations exklusive weltweite Rechte zur Herstellung und zum Vertrieb von Produkten, die Skinvisibles Technologie verwenden.
Die Partnerschaft fokussiert sich auf THC-V (Tetrahydrocannabivarin), das vielversprechend als Appetitzügler und zur Steigerung der Stoffwechselfunktionen ohne psychoaktive Effekte gilt. Das transdermale Liefersystem zielt darauf ab, gastrointestinale Nebenwirkungen zu reduzieren, die bei Obesitätstherapien häufig auftreten. Dies positioniert beide Unternehmen besser, um den globalen Obesitas-Therapiemarkt zu adressieren, der bis 2035 voraussichtlich 1,5 Billionen USD erreichen soll.
Ovation Science (OTC:OVATF) عزّزت شراكتها الاستراتيجية مع Skinvisible Pharmaceuticals لتطوير حلول مبتكرة قائمة على القنب للصحة البدنية في مجال السمنة، مع الاستفادة من تقنية التوصيل Invisicare® قيد البراءة. تحافظ الشراكة الموسعة على الحقوق الحصرية العالمية لـ Ovation في التصنيع وتوزيع المنتجات التي تستخدم تقنية Skinvisible.
تركز الشراكة على THC-V (تكهيدروكانابريفين)، الذي يبدو واعداً كمثبّط للشهية وموّدِر للوظائف الأيضية دون تأثيرات نفسية. يهدف نظام الإيصال عبر الجلد إلى تقليل الآثار الجانبية الهضمية الشائعة في علاجات السمنة. وهذا يضع الشركتين في موقع يمكنهما من استهداف سوق علاج السمنة العالمي، المتوقع أن يصل إلى حوالي 150 مليار دولار بحلول 2035.
Ovation Science (OTC:OVATF) 已加强与 Skinvisible Pharmaceuticals 的战略伙伴关系，利用正在申请专利的 Invisicare® 给药技术，开发用于肥胖市场的创新大麻素基解决方案。加强后的合作保持 Ovation 对使用 Skinvisible 技术的产品在全球范围内的独家制造和分销权。
该伙伴关系聚焦于 THC-V（四氢大麻二酚变体，tetrahydrocannabivarin），显示出作为食欲抑制剂和代谢功能增强剂的潜力且无精神活性效应。经皮给药系统旨在减少肥胖治疗中常见的胃肠道副作用。这使两家公司有能力瞄准 全球肥胖治疗市场，预计到 2035 年实现 1500 亿美元 的规模。
- Exclusive worldwide rights secured for cannabinoid-based products using Invisicare technology
- Access to new patent-pending transdermal delivery technology for glucose control
- THC-V development shows promise for obesity management without psychoactive effects
- Targeting $150 billion global obesity therapy market by 2035
- Early stage development with no immediate revenue impact
- Success dependent on clinical validation and regulatory approvals
- Faces competition in crowded obesity treatment market
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership with Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) ("Skinvisible") to leverage patent-pending Invisicare® topical and transdermal cannabis developments in the obesity market. The agreement will enhance the strategic partnership for innovative cannabinoid delivery technology with new developments and patent protection. MARKET Opportunity: The Global obesity therapy market by 2035 could reach US
Ovation and Skinvisible are building upon their original licensing and assignment agreement established on September 29, 2017. This enhanced collaboration centers on Skinvisible's proprietary Invisicare® technology for advanced polymer delivery systems targeting cannabinoid-based therapeutic products.
Exclusive Global Licensing Rights
Under the agreement, Ovation Science maintains exclusive worldwide rights to manufacture, private label, distribute, market, and promote licensed products utilizing Skinvisible's breakthrough delivery technology exclusively with cannabinoids. The agreement encompasses comprehensive access to confidential information; including proprietary formulations, processes, methodologies, specifications and trade secrets. Included is the recently filed PCT patent- pending application entitled: "Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent."
THC-V: A Promising Development for Metabolic Health
The expanded partnership specifically includes Skinvisible's latest innovation incorporating the cannabinoid THC-V (tetrahydrocannabivarin). Recent in-house research has demonstrated THC-V's potential as a therapeutic agent for obesity management, showing promising results as an appetite suppressant while improving metabolic function through enhanced insulin sensitivity and glucose control. Notably, THC-V offers these benefits without the psychoactive effects typically associated with THC. https://pubmed.ncbi.nlm.nih.gov/33526143/.
Addressing Critical Treatment Challenges
Skinvisible's Invisicare® technology represents a significant advancement in transdermal delivery systems for glucose-controlling agents. This innovative approach directly addresses one of the most persistent challenges in current obesity treatments: reducing gastrointestinal side effects that often limit patient compliance and treatment effectiveness.
The transdermal delivery method offers several advantages over traditional oral and injected medications, including improved bioavailability, reduced systemic side effects, and enhanced patient comfort and adherence to treatment protocols.
"We are excited to extend our cannabinoid development into the obesity / metabolic space," said Terry Howlett, Ovation's President. "Skinvisible has demonstrated that they can offer excellent science-based transdermal solutions. With these new developments and patent pending exclusivity we anticipate a positive impact to our financial results and creating value for our shareholders."
Market Opportunity
The global obesity therapy market presents substantial growth potential, with industry analysts projecting significant expansion through 2030. This partnership positions both companies to capitalize on the increasing demand for innovative, patient-friendly therapeutic solutions in the rapidly growing metabolic health sector.
Strategic Impact
These new developments leverage the strengths of both organizations: Skinvisible's cutting-edge delivery technology expertise and Ovation Science's cannabinoid background. Together, the companies are well-positioned to advance the development and distribution of next-generation cannabinoid-based therapeutics for metabolic disorders.
The collaboration underscores both companies' commitment to developing innovative solutions that improve patient outcomes while addressing unmet medical needs in the obesity and metabolic health markets.
About Ovation Science Inc.
Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands; ARLO CBD Beauty and InVibe® MD ("wellness" line); all powered by its in-licensed patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science team have created a unique pipeline of proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.
Stock symbols: CSE:OVAT and OTC:OVATF
Websites: CORPORATE: www.ovationscience.com
WELLNESS: www.invibemd.com BEAUTY: www.arlocbdbeauty.com
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the state or country cited, continued sales in dispensaries or in retail markets or expansion to other states or countries. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
CORPORATE and LICENSING INQUIRIES:
Doreen McMorran: info@ovationscience.com PH: 604-982-5700
SOURCE: Ovation Science Inc.
View the original press release on ACCESS Newswire
FAQ
What is the strategic partnership between Ovation Science and Skinvisible Pharmaceuticals?
How does OVATF's THC-V technology work for obesity treatment?
What is the market potential for Ovation Science's obesity treatment technology?
What advantages does Ovation's transdermal delivery system offer for obesity treatment?
When did the original partnership between OVATF and Skinvisible begin?
